Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, Zhao H, Marathe A, Kotch L, Jee J, Wang Y, Zhou L, Adams WM, Jarral V, Pilaro A, Lostritto R, Gootenberg JE, Keegan P, Pazdur R. Donoghue M, et al. Among authors: keegan p. Clin Cancer Res. 2012 Mar 15;18(6):1496-505. doi: 10.1158/1078-0432.CCR-11-2149. Epub 2012 Jan 26. Clin Cancer Res. 2012. PMID: 22282463
Study design in the evaluation of breast cancer imaging technologies.
Houn F, Bright RA, Bushar HF, Croft BY, Finder CA, Gohagan JK, Jennings RJ, Keegan P, Kessler LG, Kramer BS, Martynec LO, Robinowitz M, Sacks WM, Schultz DG, Wagner RF. Houn F, et al. Among authors: keegan p. Acad Radiol. 2000 Sep;7(9):684-92. doi: 10.1016/s1076-6332(00)80524-3. Acad Radiol. 2000. PMID: 10987329
FDA drug approval summary: panitumumab (Vectibix).
Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. Giusti RM, et al. Among authors: keegan p. Oncologist. 2007 May;12(5):577-83. doi: 10.1634/theoncologist.12-5-577. Oncologist. 2007. PMID: 17522246 Free article. Clinical Trial.
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R. Giusti RM, et al. Among authors: keegan p. Clin Cancer Res. 2008 Mar 1;14(5):1296-302. doi: 10.1158/1078-0432.CCR-07-1354. Clin Cancer Res. 2008. PMID: 18316547 Clinical Trial.
183 results